한글목차

세계의 유방 생검 기기 시장 규모는 2025년 23억 8,410만 달러에서 2030년까지 32억 6,170만 달러에 달할 것으로 예측되며, 예측 기간에 CAGR 6.5%의 성장이 전망됩니다.

유방암 발병률 증가, 조기 발견의 중요성에 대한 인식 증가, 최소침습적 진단 절차에 대한 선호도 증가 등 복합적인 요인으로 인해 시장이 수혜를 받고 있습니다. 또한, 주 및 지역 검진 프로그램은 잠재적 유방암에 대한 여성들의 검진율을 크게 향상시키고 있습니다.

생검 바늘 부문은 2024년 시장에서 가장 큰 점유율을 차지했습니다.

생검침은 높은 정확도와 최소한의 침습으로 병리조직학적 분석에 사용되는 조직 샘플을 채취할 수 있어 유방암 진단에 필수적인 도구가 되고 있습니다. 생검침은 코어 니들 생검(CNB), 세침흡입 생검(FNAB), 흡입식 조직 생검(VAB)에 사용할 수 있으며, 각각 특정 임상 시나리오와 병변의 다양한 특징에 맞게 설계되어 있습니다. 바늘 생검은 외과적 생검에 비해 환자의 불편감이 적고, 진단 결과가 빠르며, 시술과 회복에 소요되는 시간이 짧아 선호되고 있습니다.

바늘 유방 생검 시술 부문이 2024년 가장 큰 시장 점유율을 차지했습니다.

침습적 유방 생검 부문의 성장은 여러 가지 요인에 의해 촉진되고 있습니다. 유방암 발병률 증가, 조기 진단에 대한 중요성, 최소침습적 수술에 대한 환자 선호도 증가 등이 그 예입니다. 특히 영상 유도 및 바늘 설계의 기술 발전은 불편함과 불편함을 최소화하면서 바늘유방생검의 정확도를 높이고 있습니다. 이로 인해 환자들에게 보다 수용 가능하고 실행 가능한 시술이 되고 있습니다. 또한, 유방암 검진 프로그램의 확립, 유리한 재원조달 정책, 여성 건강 문제에 대한 인식의 증가도 시장 성장에 기여하고 있습니다. 또한, 외래 치료 선호와 비용 효율적인 진단 옵션에 대한 관심이 증가함에 따라 다양한 의료 환경에서 바늘 유방 생검이 폭넓게 수용되고 있습니다.

액체 생검 부문은 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다.

액체 생검 부문은 비침습적이고 정확한 실시간 암 진단 솔루션에 대한 수요 증가로 성장세를 보이고 있습니다. 액체 생검은 혈액 내 순환종양세포(CTC)와 순환종양 DNA(ctDNA)를 검출하는 과정으로, 기존 조직 생검보다 덜 침습적입니다. 이를 통해 조기 진단, 치료 효과 추적, 질병의 재발 및 진행을 효과적으로 모니터링할 수 있습니다. 액체 생검 시장의 성장에는 유방암 발병률 증가, 정밀의료의 발전, 차세대 염기서열분석(NGS) 및 디지털 PCR을 중심으로 한 분자진단 기술의 향상 등 여러 요인이 있습니다. 액체 생검의 임상적 유용성 증가와 일상적인 사용은 액체 생검의 장점에 대한 인식이 높아지고 규제정책이 강화됨에 따라 전 세계적으로 액체 생검 기술의 채택을 더욱 촉진하고 있습니다.

조기 암 검진 부문이 2024년 시장을 장악했습니다.

조기 암 검진은 암을 치료 가능한 초기 단계에서 발견하여 사망률을 낮추고 치료 결과를 개선하는 데 중요한 역할을 하기 때문에 가장 큰 시장 점유율을 차지하고 있습니다. 전 세계 암 발병률의 증가, 특히 취약한 노년층의 암 발병률 증가로 인해 효과적인 질병 모니터링의 필요성이 증가하고 있습니다. 그 결과, 기술의 발전은 조기 예방적 건강 모니터링 및 건강 검진에 중요한 촉진제가 되고 있습니다.

세계의 유방 생검 기기 시장에 대해 조사 분석했으며, 주요 촉진요인과 억제요인, 경쟁 상황, 향후 동향 등의 정보를 전해드립니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 주요 조사 결과

• 유방 생검 기기 시장 개요
• 유방 생검 기기 시장 : 지역별(2025년·2030년)
• 유럽의 유방 생검 기기 시장 : 지역별, 용도별(2024년)
• 유방 생검 기기 시장 지리적 현황

제5장 시장 개요

• 소개
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 규제 분석
  • 규제기관, 정부기관, 기타 조직
  • 규제 상황
• 밸류체인 분석
• 공급망 분석
  • 저명 기업
  • 중소기업
  • 최종사용자
• 생태계 분석
• 기술 분석
  • 주요 기술
  • 보완 기술
  • 인접 기술
• 무역 분석
  • 수입 데이터
  • 수출 데이터
• 특허 분석
• Porter's Five Forces 분석
• 가격 분석
  • 유방 생검 기기 평균판매가격 동향 : 지역별
  • 유방 생검 기기 평균판매가격 : 용도별
• 사례 연구 분석
• 주요 회의와 이벤트(2025-2026년)
• 주요 이해관계자와 구입 기준
• 유방 생검 기기 시장에 대한 2025년 미국 관세의 영향
  • 소개
  • 주요 관세율
  • 가격의 영향 분석
  • 국가/지역에 대한 영향
  • 최종 이용 산업에 대한 영향
• 유방 생검 기기 시장에 대한 생성형 AI/AI의 영향
• 투자와 자금 조달 시나리오

제6장 유방 생검 기기 시장 : 시술별

• 소개
• 바늘 유방 생검
  • 코어 니들 생검
  • 흡인식 조직 생검(VAB)
  • 세침흡인 생검(FNAB)
• 외과적 유방 생검
  • 절제 생검
  • 절개 생검
• 액체 유방 생검
  • 순환 종양 세포
  • 순환 종양 DNA(ctDNA)
  • 기타 바이오마커

제7장 유방 생검 기기 시장 : 제품별

• 소개
• 생검침
  • 코어 니들
  • 세흡인침
  • 흡인식 조직 생검침
• 생검 기기
  • 코어 생검 기기
  • 흡인식 조직 생검 기기
• 유도 시스템
  • 맘모그래피 유도정위생검
  • 초음파 유도 생검
  • MRI 유도 생검
• 생검 테이블
• 어세이 키트
• 액체 생검 장비
• 로컬라이제이션 와이어
• 기타 제품

제8장 유방 생검 시장 : 용도별

• 소개
• 조기 암 검진
• 치료 선택
• 치료 모니터링
• 재발 모니터링

제9장 유방 생검 기기 시장 : 최종사용자별

• 소개
• 병원·진료소
• 영상 진단 클리닉·진단 센터
• 유방 케어 센터

제10장 유방 생검 기기 시장 : 지역별

• 소개
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
• 중동 및 아프리카

제11장 경쟁 구도

• 소개
• 주요 진출 기업 전략/강점
• 매출 분석(2020-2024년)
• 시장 점유율 분석(2024년)
• 기업 평가 매트릭스 : 주요 기업(2024년)
• 기업 평가 매트릭스 : 스타트업/중소기업(2024년)
• 기업 평가와 재무 지표
  • 재무 지표
  • 기업 평가
• 브랜드/제품의 비교
• 경쟁 시나리오

제12장 기업 개요

• 주요 기업
  • HOLOGIC, INC.
  • DANAHER CORPORATION
  • BECTON, DICKINSON AND COMPANY
  • ARGON MEDICAL
  • QIAGEN
  • MERIT MEDICAL SYSTEMS
  • MENARINI SILICON BIOSYSTEMS SPA
  • GUARDANT HEALTH, INC.
  • NEOGENOMICS LABORATORIES, INC.
  • STERYLAB S.R.L
  • BIOCEPT, INC.
  • BIO-RAD LABORATORIES, INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • EXACT SCIENCES CORPORATION
  • SYSMEX INOSTICS(A SUBSIDIARY OF SYSMEX CORPORATION)
  • THERMO FISHER SCIENTIFIC
  • FUJIFILM HOLDINGS CORPORATION
• 기타 기업
  • CARDIFF ONCOLOGY INC.
  • MYRIAD GENETICS, INC.
  • ILLUMINA, INC.
  • FLUXION BIOSCIENCES, INC.
  • INRAD, INC.
  • IZI MEDICAL PRODUCTS
  • REMINGTON MEDICAL INC.
  • CP MEDICAL

제13장 부록

영문목차

The global market for breast biopsy devices is expected to reach USD 3,261.7 million by 2030 from USD 2,384.1 million in 2025, representing a CAGR of 6.5% during the forecast period. The market is benefiting from a combination of factors, including rising breast cancer rates, increased awareness of the importance of early detection, and the growing preference for minimally invasive diagnostic procedures. Additionally, state and provincial screening programs are significantly improving the rate of screenings among women for potential breast cancer.

The biopsy needles segment held the largest share of the market in 2024.

Based on type, the breast biopsy devices market is divided into several segments: biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other devices. Among these, the biopsy needles segment holds a significant share of the market. Biopsy needles are essential tools for diagnosing breast cancer, as they collect tissue samples for histopathological analysis with high accuracy and minimal invasiveness. They can be utilized in core-needle biopsy (CNB), fine-needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB), each designed for specific clinical scenarios and the varying characteristics of the lesions. Biopsy needles are preferred because they provide diagnostic results with less discomfort for the patient and require less time for both the procedure and recovery compared to surgical biopsies.

The needle breast biopsy procedure segment accounted for the largest market share in 2024.

Based on procedures, the breast biopsy devices market can be broadly categorized into three types: needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. The growth of the needle breast biopsy segment is driven by several key factors. These include rising breast cancer rates, a greater emphasis on early and accurate diagnosis, and an increasing preference among patients for minimally invasive procedures. Advancements in technology, particularly in image guidance and needle design, have enhanced the accuracy of needle breast biopsies while minimizing discomfort and inconvenience. This has made the procedure more acceptable and feasible for patients. Furthermore, the establishment of breast cancer screening programs, more favorable reimbursement policies, and heightened awareness of women's health issues are also contributing to market growth. Additionally, the preference for outpatient care and the growing interest in cost-effective diagnostic options have led to broader acceptance of needle breast biopsies across various healthcare settings.

The liquid biopsy segment is projected to register the highest CAGR during the forecast period.

The breast biopsy devices market is primarily categorized into three main techniques: image-guided biopsy, liquid biopsy, and other methods. The liquid biopsy segment is experiencing growth due to the increasing demand for non-invasive, accurate, and real-time cancer diagnostic solutions. Liquid biopsy processes detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the blood, making them less invasive than traditional tissue biopsies. This allows for earlier diagnoses, better tracking of treatment responses, and effective monitoring for recurrence or progression of the disease. Several factors are driving the growth of the liquid biopsy market, including the rising incidence of breast cancer, the advancement of precision (or personalized) medicine, and improvements in molecular diagnostic technologies, particularly through next-generation sequencing (NGS) and digital PCR. The increasing clinical utility and routine application of liquid biopsies, along with a growing awareness of their benefits and supportive regulatory policies, are further promoting the global adoption of these technologies.

The early cancer screening segment dominated the market in 2024.

The breast biopsy market can be broadly categorized based on its applications into four main areas: early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Early cancer screening holds the largest market share as it plays a crucial role in reducing mortality rates and improving treatment outcomes by detecting cancer at the earliest and most treatable stage. The rising incidence of cancer globally, particularly among vulnerable and aging populations, has increased the need for effective illness monitoring. Consequently, advancements in technology will serve as a significant driver for early and proactive health monitoring and diagnosis.

Asia Pacific is expected to register a significant growth rate in the market during the forecast period.

The breast biopsy market is experiencing the highest growth in the Asia Pacific region due to several converging factors. These include an increasing incidence of breast cancer, the development of healthcare infrastructure, and greater awareness of the importance of early cancer detection. Countries such as China, India, and Japan are making significant investments in interventional and diagnostic imaging, which is creating a demand for advanced biopsy technologies. Additionally, government support, improved access to medical care in rural areas, and the expansion of global medical device companies promoting their products in emerging markets are driving this adoption. Furthermore, the region's large population and rising healthcare spending are key drivers of its double-digit market growth.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (27%), Director-level Executives (18%), and Other Designations (55%)
• By Region: North America (50%), Europe (20%), Asia Pacific (15%), Latin America (10%), and the Middle East & Africa (5%)

Prominent players in this market are Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Germany), and Exact Sciences Corporation (US).

Research Coverage

• The report studies the breast biopsy devices market by product, procedure, application, end user, and region.
• The report analyzes factors affecting market growth (drivers, restraints, opportunities, and challenges).
• The report evaluates the market opportunities and challenges for stakeholders and details the competitive landscape for market leaders.
• The report studies micromarkets with respect to their growth trends, prospects, and contributions to the global breast biopsy devices market.
• The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report is designed to assist both new entrants and established market leaders, as well as smaller companies in the breast biopsy devices sector, in making informed investment decisions. It provides comprehensive data that supports risk evaluation and validated investment strategies. The report features detailed market segmentation based on end users and regional aspects, enabling you to focus on specific segments. Additionally, it offers thorough coverage and analysis of trends, challenges, growth opportunities, and future prospects, ensuring that your decisions are well-informed and considerate of all relevant factors.

The report provides insights into the following pointers:

• Analysis of key drivers (ongoing innovations in biopsy needle designs and liquid biopsy technologies), restraints (high costs associated with advanced biopsy equipment and imaging technologies and stringent regulatory approval procedures), opportunities (technological advancements in imaging technology), and challenges (accuracy and reliability of certain biopsy procedures), influencing the growth of the breast biopsy devices market.
• Product Development/Innovation: Detailed insights into upcoming technologies, R&D activities, and new product & service launches in the breast biopsy devices market.
• Market Diversification: Exhaustive information about untapped geographies, new products, recent developments, and investments in the breast biopsy devices market.
• Market Development: Comprehensive information about lucrative markets-the report analyzes the breast biopsy devices market across varied regions.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), QIAGEN (Germany), and Biocept, Inc. (US), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STUDY LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Objectives of secondary research
    • 2.1.1.3 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH (REVENUE SHARE ANALYSIS)
    • 2.2.1.1 Company revenue estimation approach
    • 2.2.1.2 Customer-based market estimation
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ASSESSMENT
• 2.5 STUDY ASSUMPTIONS
  • 2.5.1 MARKET ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BREAST BIOPSY DEVICES MARKET OVERVIEW
• 4.2 BREAST BIOPSY DEVICES MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
• 4.3 EUROPE: BREAST BIOPSY DEVICES MARKET, BY REGION AND APPLICATION, 2024
• 4.4 GEOGRAPHIC SNAPSHOT OF BREAST BIOPSY DEVICES MARKET

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing incidence of breast cancer
    • 5.2.1.2 Expansion of private diagnostic chains and imaging centers
    • 5.2.1.3 Increasing demand for minimally invasive and non-invasive procedures
    • 5.2.1.4 Growing awareness regarding early detection of breast cancer
    • 5.2.1.5 Improved reimbursement scenario
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of liquid biopsy tests
    • 5.2.2.2 Stringent regulatory approval procedures
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Technological advancements
    • 5.2.3.2 Growing collaboration and financial support from public and private sectors
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Shortage of skilled professionals
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
  • 5.3.2 REGULATORY LANDSCAPE
    • 5.3.2.1 North America
      • 5.3.2.1.1 US
      • 5.3.2.1.2 Canada
    • 5.3.2.2 Europe
    • 5.3.2.3 Asia Pacific
      • 5.3.2.3.1 Japan
      • 5.3.2.3.2 China
      • 5.3.2.3.3 India
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
  • 5.5.1 PROMINENT COMPANIES
  • 5.5.2 SMALL & MEDIUM-SIZED ENTERPRISES
  • 5.5.3 END USERS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Ultrasound
    • 5.7.1.2 Mammography-guided stereotactic biopsy
    • 5.7.1.3 MRI
    • 5.7.1.4 Contrast-enhanced mammography (CEM) guidance
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Gamma-guided biopsy systems
    • 5.7.2.2 Molecular breast imaging (MBI)-guided biopsy
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Surgical oncology technologies
    • 5.7.3.2 Cryoablation and other minimally invasive ablation technologies
• 5.8 TRADE ANALYSIS
  • 5.8.1 IMPORT DATA
  • 5.8.2 EXPORT DATA
• 5.9 PATENT ANALYSIS
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 THREAT OF NEW ENTRANTS
  • 5.10.2 THREAT OF SUBSTITUTES
  • 5.10.3 BARGAINING POWER OF SUPPLIERS
  • 5.10.4 BARGAINING POWER OF BUYERS
  • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE TREND OF BREAST BIOPSY DEVICES, BY REGION
  • 5.11.2 AVERAGE SELLING PRICE OF BREAST BIOPSY DEVICES, BY APPLICATION
• 5.12 CASE STUDY ANALYSIS
  • 5.12.1 CASE STUDY 1: PET-GUIDED BREAST BIOPSY
  • 5.12.2 CASE STUDY 2: EARLY-STAGE BREAST CANCER AMID COVID PANDEMIC
  • 5.12.3 CASE STUDY 3: SAMPLING MULTIPLE SMALL LESIONS IN DENSE BREAST TISSUE
• 5.13 KEY CONFERENCES & EVENTS, 2025-2026
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS
  • 5.14.2 BUYING CRITERIA
• 5.15 IMPACT OF 2025 US TARIFF ON BREAST BIOPSY DEVICES MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 KEY TARIFF RATES
  • 5.15.3 PRICE IMPACT ANALYSIS
  • 5.15.4 IMPACT ON COUNTRY/REGION
    • 5.15.4.1 US
    • 5.15.4.2 Europe
    • 5.15.4.3 Asia Pacific
  • 5.15.5 IMPACT ON END-USE INDUSTRIES
• 5.16 IMPACT OF GENERATIVE AI/AI ON BREAST BIOPSY DEVICES MARKET
• 5.17 INVESTMENT & FUNDING SCENARIO

6 BREAST BIOPSY DEVICES MARKET, BY PROCEDURE

• 6.1 INTRODUCTION
• 6.2 NEEDLE BREAST BIOPSY
  • 6.2.1 CORE NEEDLE BIOPSY
    • 6.2.1.1 Procedural advantages of guidance system-based biopsy to drive revenue growth
  • 6.2.2 VACUUM-ASSISTED BIOPSY (VAB)
    • 6.2.2.1 High diagnostic specificity and accuracy of technique to boost demand
  • 6.2.3 FINE NEEDLE ASPIRATION BIOPSY (FNAB)
    • 6.2.3.1 Drawbacks associated with procedure to limit market growth
• 6.3 OPEN SURGICAL BREAST BIOPSY
  • 6.3.1 EXCISIONAL BIOPSY
    • 6.3.1.1 Risk of post-operative complications to hinder market growth
  • 6.3.2 INCISIONAL BIOPSY
    • 6.3.2.1 Longer recovery period associated with incisional biopsy to restrict growth
• 6.4 LIQUID BREAST BIOPSY
  • 6.4.1 CIRCULATING TUMOR CELLS
    • 6.4.1.1 Ability to provide important information on molecular properties of breast tumors to boost market
  • 6.4.2 CIRCULATING TUMOR DNA (CTDNA)
    • 6.4.2.1 Low concentrations of ctDNA to make screening for clinically relevant mutations challenging
  • 6.4.3 OTHER BIOMARKERS

7 BREAST BIOPSY DEVICES MARKET, BY PRODUCT

• 7.1 INTRODUCTION
• 7.2 BIOPSY NEEDLES
  • 7.2.1 CORE NEEDLES
    • 7.2.1.1 Early detection through core needle biopsy to boost growth
  • 7.2.2 FINE ASPIRATION NEEDLES
    • 7.2.2.1 Accurate clinical decisions for early cancer diagnosis to drive demand for fine aspiration needles
  • 7.2.3 VACUUM-ASSISTED BIOPSY NEEDLES
    • 7.2.3.1 Enhanced accuracy with vacuum-assisted tissue sampling to drive adoption
• 7.3 BIOPSY EQUIPMENT
  • 7.3.1 CORE BIOPSY EQUIPMENT
    • 7.3.1.1 Ability to streamline breast diagnosis with core biopsy technology to boost demand
  • 7.3.2 VACUUM-ASSISTED BIOPSY EQUIPMENT
    • 7.3.2.1 Advantages of VAB in breast biopsy to drive market growth
• 7.4 GUIDANCE SYSTEMS
  • 7.4.1 MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY
    • 7.4.1.1 Advantages of technique to boost adoption in coming years
  • 7.4.2 ULTRASOUND-GUIDED BIOPSY
    • 7.4.2.1 Ability to create fine-grained pictures of breasts to drive growth
  • 7.4.3 MRI-GUIDED BIOPSY
    • 7.4.3.1 High cost and low specificity to affect demand
• 7.5 BIOPSY TABLES
  • 7.5.1 GROWING USE OF BIOPSY TABLES TO PERFORM STEREOTACTIC BIOPSY PROCEDURES TO FAVOR MARKET GROWTH
• 7.6 ASSAY KITS
  • 7.6.1 PRODUCT APPROVALS AND LAUNCHES TO DRIVE SEGMENTAL GROWTH
• 7.7 LIQUID BIOPSY INSTRUMENTS
  • 7.7.1 ONGOING RESEARCH AND CLINICAL TRIALS TO DELIVER NOVEL SOLUTIONS IN MARKET
• 7.8 LOCALIZATION WIRES
  • 7.8.1 WIDE USAGE OF LOCALIZATION WIRES TO LOCATE BREAST ABNORMALITIES AND LUMPS TO BOOST MARKET
• 7.9 OTHER PRODUCTS

8 BREAST BIOPSY MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 EARLY CANCER SCREENING
  • 8.2.1 GROWING AWARENESS ABOUT EARLY CANCER DETECTION TO DRIVE SEGMENT GROWTH
• 8.3 THERAPY SELECTION
  • 8.3.1 ABILITY OF PERSONALIZED THERAPY SELECTION TO ENHANCE TREATMENT EFFICACY TO DRIVE DEMAND
• 8.4 TREATMENT MONITORING
  • 8.4.1 GROWING POPULARITY OF REAL-TIME TREATMENT MONITORING TO BOOST MARKET
• 8.5 RECURRENCE MONITORING
  • 8.5.1 UNMET CLINICAL NEEDS TO CREATE OPPORTUNITIES FOR PLAYERS IN MARKET

9 BREAST BIOPSY DEVICES MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS & CLINICS
  • 9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO BOOST MARKET
• 9.3 IMAGING CLINICS & DIAGNOSTIC CENTERS
  • 9.3.1 RISING NUMBER OF PRIVATE IMAGING CENTERS TO CONTRIBUTE TO MARKET GROWTH
• 9.4 BREAST CARE CENTERS
  • 9.4.1 INCREASING POPULARITY OF BREAST CARE CENTERS IN DEVELOPED COUNTRIES TO BOOST MARKET

10 BREAST BIOPSY DEVICES MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 US to dominate North America breast biopsy devices market during forecast period
  • 10.2.3 CANADA
    • 10.2.3.1 Surge in incidence of breast cancer and favorable government guidelines to support market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Favorable changes in reimbursement scenario to fuel adoption of technologically advanced products in Germany
  • 10.3.3 UK
    • 10.3.3.1 Initiatives by public & private organizations to increase awareness about breast cancer to drive growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Rising geriatric population to support market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Evolving regulatory scenario for breast biopsy to boost market
  • 10.3.6 SPAIN
    • 10.3.6.1 Increased funding scenario to propel market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Presence of universal healthcare reimbursement scenario and rising breast cancer cases
  • 10.4.4 INDIA
    • 10.4.4.1 Government initiatives to improve female health to drive market growth in India
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Rising research investments and awareness campaigns to support market growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Rising R&D and promising clinical trials in country to positively impact market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Key market in Latin America owing to modernization of healthcare facilities
  • 10.5.3 MEXICO
    • 10.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN MEA REGION
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.3 GCC COUNTRIES
    • 10.6.3.1 Growing healthcare infrastructure to fuel market growth
  • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2024)
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Product footprint
    • 11.5.5.4 Procedure footprint
    • 11.5.5.5 Application footprint
    • 11.5.5.6 End-user footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES (2024)
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.6.5.1 Detailed list of key startups/SMEs
    • 11.6.5.2 Competitive benchmarking of startup/SME players, by region
    • 11.6.5.3 Competitive benchmarking of startup/SME players, product
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 THIS SEGMENT INCLUDES THE GROWTH STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE BREAST BIOPSY DEVICES MARKET BETWEEN JANUARY 2020 AND MAY 2025.
  • 11.9.2 PRODUCT LAUNCHES & APPROVALS
  • 11.9.3 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 HOLOGIC, INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
      • 12.1.1.2.1 Deals
    • 12.1.1.3 MnM view
      • 12.1.1.3.1 Key strengths
      • 12.1.1.3.2 Strategic choices
      • 12.1.1.3.3 Weaknesses & competitive threats
  • 12.1.2 DANAHER CORPORATION
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches & approvals
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 BECTON, DICKINSON AND COMPANY
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 MnM View
      • 12.1.3.3.1 Key strengths
      • 12.1.3.3.2 Strategic choices
      • 12.1.3.3.3 Weaknesses & competitive threats
  • 12.1.4 ARGON MEDICAL
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches & approvals
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 QIAGEN
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 MERIT MEDICAL SYSTEMS
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches & approvals
      • 12.1.6.3.2 Deals
  • 12.1.7 MENARINI SILICON BIOSYSTEMS SPA
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches & approvals
      • 12.1.7.3.2 Deals
  • 12.1.8 GUARDANT HEALTH, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches & approvals
      • 12.1.8.3.2 Deals
      • 12.1.8.3.3 Other developments
  • 12.1.9 NEOGENOMICS LABORATORIES, INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches & approvals
      • 12.1.9.3.2 Deals
  • 12.1.10 STERYLAB S.R.L
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 BIOCEPT, INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 BIO-RAD LABORATORIES, INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product launches & approvals
  • 12.1.13 F. HOFFMANN-LA ROCHE LTD.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 EXACT SCIENCES CORPORATION
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Deals
  • 12.1.15 SYSMEX INOSTICS (A SUBSIDIARY OF SYSMEX CORPORATION)
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Deals
  • 12.1.16 THERMO FISHER SCIENTIFIC
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Deals
  • 12.1.17 FUJIFILM HOLDINGS CORPORATION
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 CARDIFF ONCOLOGY INC.
  • 12.2.2 MYRIAD GENETICS, INC.
  • 12.2.3 ILLUMINA, INC.
  • 12.2.4 FLUXION BIOSCIENCES, INC.
  • 12.2.5 INRAD, INC.
  • 12.2.6 IZI MEDICAL PRODUCTS
  • 12.2.7 REMINGTON MEDICAL INC.
  • 12.2.8 CP MEDICAL

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS